The global gene modifying immunotherapy for blood cancer market is expected to grow at a CAGR of 16.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing prevalence of blood cancer and rising awareness about gene therapy among patients.
The global gene modifying immunotherapy for blood cancer market is segmented on the basis of type, application, and region. On the basis of type, it is segmented into CAR cell therapy, TCR cell therapy, and gene modifying immunotherapy for blood cancer. On the basis of application, it is segmented into acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma (B-CLL), multiple myeloma (MM). On the basis of region it includes North America, Latin America, Europe Asia Pacific and Middle East & Africa regions.
- Increasing prevalence of blood cancer globally is one of the major factors driving the growth of this market.
- Increasing awareness about gene modifying immunotherapy for blood cancer among patients and physicians is also driving the growth of this market.
- Availability and affordability are some other factors that are driving the growth of this market.
- Lack of awareness about gene modifying immunotherapy for blood cancer among patients and physicians is one factor that may hamper the growth rate.
Industry Growth Insights published a new data on “Gene Modifying Immunotherapy for Blood Cancer Market”. The research report is titled “Gene Modifying Immunotherapy for Blood Cancer Market research by Types (CAR T-cell Therapy, TCR T-cell Therapy, Gene Modifying Immunotherapy for Blood Cance), By Applications (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, B Cell Lymphoma, Multiple Myeloma, Other), By Players/Companies Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals, Mustang Bio, Gene Modifying Immunotherapy for Blood Cance”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Gene Modifying Immunotherapy for Blood Cancer Market Research Report
By Type
CAR T-cell Therapy, TCR T-cell Therapy, Gene Modifying Immunotherapy for Blood Cance
By Application
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, B Cell Lymphoma, Multiple Myeloma, Other
By Companies
Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals, Mustang Bio, Gene Modifying Immunotherapy for Blood Cance
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Gene Modifying Immunotherapy for Blood Cancer Market Report Segments:
The global Gene Modifying Immunotherapy for Blood Cancer market is segmented on the basis of:
Types
CAR T-cell Therapy, TCR T-cell Therapy, Gene Modifying Immunotherapy for Blood Cance
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, B Cell Lymphoma, Multiple Myeloma, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Kite Pharma
- Juno Therapeutics
- Cellectis
- Ziopharm Oncology
- Celyad
- Bluebird Bio
- Bellicum Pharmaceuticals
- Mustang Bio
- Gene Modifying Immunotherapy for Blood Cance
Highlights of The Gene Modifying Immunotherapy for Blood Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CAR T-cell Therapy
- TCR T-cell Therapy
- Gene Modifying Immunotherapy for Blood Cance
- By Application:
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- B Cell Lymphoma
- Multiple Myeloma
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gene Modifying Immunotherapy for Blood Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gene modifying immunotherapy (GMIT) is a type of cancer treatment that uses genetic engineering to help the body's immune system fight cancer. GMIT can be used to treat several types of blood cancers, including leukemia and lymphoma.
Some of the major companies in the gene modifying immunotherapy for blood cancer market are Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals, Mustang Bio, Gene Modifying Immunotherapy for Blood Cance.
The gene modifying immunotherapy for blood cancer market is expected to register a CAGR of 16.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Gene Modifying Immunotherapy for Blood Cancer Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Gene Modifying Immunotherapy for Blood Cancer Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Gene Modifying Immunotherapy for Blood Cancer Market - Supply Chain
4.5. Global Gene Modifying Immunotherapy for Blood Cancer Market Forecast
4.5.1. Gene Modifying Immunotherapy for Blood Cancer Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Gene Modifying Immunotherapy for Blood Cancer Market Size (000 Units) and Y-o-Y Growth
4.5.3. Gene Modifying Immunotherapy for Blood Cancer Market Absolute $ Opportunity
5. Global Gene Modifying Immunotherapy for Blood Cancer Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Type
5.3.1. CAR T-cell Therapy
5.3.2. TCR T-cell Therapy
5.3.3. Gene Modifying Immunotherapy for Blood Cance
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Gene Modifying Immunotherapy for Blood Cancer Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Application
6.3.1. Acute Lymphocytic Leukemia
6.3.2. Chronic Lymphocytic Leukemia
6.3.3. B Cell Lymphoma
6.3.4. Multiple Myeloma
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Gene Modifying Immunotherapy for Blood Cancer Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Gene Modifying Immunotherapy for Blood Cancer Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Gene Modifying Immunotherapy for Blood Cancer Demand Share Forecast, 2019-2026
9. North America Gene Modifying Immunotherapy for Blood Cancer Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Application
9.4.1. Acute Lymphocytic Leukemia
9.4.2. Chronic Lymphocytic Leukemia
9.4.3. B Cell Lymphoma
9.4.4. Multiple Myeloma
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Type
9.7.1. CAR T-cell Therapy
9.7.2. TCR T-cell Therapy
9.7.3. Gene Modifying Immunotherapy for Blood Cance
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Gene Modifying Immunotherapy for Blood Cancer Demand Share Forecast, 2019-2026
10. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Application
10.4.1. Acute Lymphocytic Leukemia
10.4.2. Chronic Lymphocytic Leukemia
10.4.3. B Cell Lymphoma
10.4.4. Multiple Myeloma
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Type
10.7.1. CAR T-cell Therapy
10.7.2. TCR T-cell Therapy
10.7.3. Gene Modifying Immunotherapy for Blood Cance
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Gene Modifying Immunotherapy for Blood Cancer Demand Share Forecast, 2019-2026
11. Europe Gene Modifying Immunotherapy for Blood Cancer Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Application
11.4.1. Acute Lymphocytic Leukemia
11.4.2. Chronic Lymphocytic Leukemia
11.4.3. B Cell Lymphoma
11.4.4. Multiple Myeloma
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Type
11.7.1. CAR T-cell Therapy
11.7.2. TCR T-cell Therapy
11.7.3. Gene Modifying Immunotherapy for Blood Cance
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Gene Modifying Immunotherapy for Blood Cancer Demand Share, 2019-2026
12. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Application
12.4.1. Acute Lymphocytic Leukemia
12.4.2. Chronic Lymphocytic Leukemia
12.4.3. B Cell Lymphoma
12.4.4. Multiple Myeloma
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Type
12.7.1. CAR T-cell Therapy
12.7.2. TCR T-cell Therapy
12.7.3. Gene Modifying Immunotherapy for Blood Cance
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Demand Share, 2019-2026
13. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Application
13.4.1. Acute Lymphocytic Leukemia
13.4.2. Chronic Lymphocytic Leukemia
13.4.3. B Cell Lymphoma
13.4.4. Multiple Myeloma
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size and Volume Forecast by Type
13.7.1. CAR T-cell Therapy
13.7.2. TCR T-cell Therapy
13.7.3. Gene Modifying Immunotherapy for Blood Cance
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Gene Modifying Immunotherapy for Blood Cancer Market: Market Share Analysis
14.2. Gene Modifying Immunotherapy for Blood Cancer Distributors and Customers
14.3. Gene Modifying Immunotherapy for Blood Cancer Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Kite Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Juno Therapeutics
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Cellectis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Ziopharm Oncology
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Celyad
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bluebird Bio
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bellicum Pharmaceuticals
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Mustang Bio
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Gene Modifying Immunotherapy for Blood Cance
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
&n
